Cardiology – Page 5

Paclitaxel-coated vs Uncoated Devices in Infrainguinal Revascularisation: Insights from the SWEDEPAD 2 Trial

By MedXY 09/17/2025

The SWEDEPAD 2 trial reveals that paclitaxel-coated devices do not improve quality of life at 1 year and raise concerns about increased 5-year mortality in patients with intermittent claudication undergoing lower limb revascularisation.

Cardiology news Specialties

Paclitaxel-Coated vs Uncoated Devices in Chronic Limb-Threatening Ischaemia: Insights from the SWEDEPAD 1 Trial

By MedXY 09/17/2025

The SWEDEPAD 1 trial evaluated paclitaxel-coated versus uncoated devices for infrainguinal revascularisation in chronic limb-threatening ischaemia, finding no significant reduction in major amputations or mortality over a median 2.7-year follow-up.

Cardiology Clinical Updates news Specialties

MAR001: A Promising ANGPTL4 Inhibitor for Safe and Effective Lipid Lowering

By MedXY 09/17/2025

Phase 1 and 1b/2a trials demonstrate that MAR001, an ANGPTL4 inhibitory antibody, safely reduces triglycerides and remnant cholesterol, supporting its potential to lower ASCVD risk beyond current therapies.

Cardiology Family Medicine & Nutrition Specialties

Long-Term Outcomes of the DASH Intervention in Nonobstructive Coronary Artery Disease: Follow-Up of the DISCO-CT Study

By MedXY 09/16/2025

A one-year DASH diet intervention led to sustained suppression of proatherogenic chemokine CXCL4 and fewer major cardiovascular events over six years despite reduced adherence and partial loss of initial benefits in nonobstructive CAD patients.

Cardiology Critical Care Medical News news Specialties

Sudden Death Is Not So Sudden: Understanding, Preventing, and Responding to Cardiac Arrest

By MedXY 09/14/2025

Sudden death, often caused by heart conditions, is typically the culmination of gradual damage. This article explores warning signs, emergency response, and crucial prevention strategies to protect your heart and save lives.

AI Cardiology Specialties

Harnessing Machine Learning to Predict High-Risk Coronary Artery Disease: Insights from the SCOT-HEART Trial

By MedXY 09/14/2025

Machine learning models trained on clinical data improve prediction of coronary artery disease on CT scans compared to traditional risk scores, potentially guiding better resource utilization in cardiovascular care.

AI Cardiology news Specialties

Harnessing AI: LLM-Based Conversational Agents Reduce Depression and Anxiety Among Young Adults in Short Video App Trial

By MedXY 09/14/2025

A 28-day RCT demonstrates that a conversational AI trained on a large language model effectively reduces mild depression and anxiety symptoms in young adults through dialog interventions integrated in short video apps.

Cardiology General Surgery news Specialties

Unexpected Risks of Postoperative 20% Albumin Infusion in High-Risk Cardiac Surgery Patients: Insights from the ALBICS AKI Trial

By MedXY 09/13/2025

The ALBICS AKI trial reveals that postoperative infusion of 20% albumin increases acute kidney injury risk in high-risk cardiac surgery patients, challenging prior assumptions about albumin's nephroprotective role in this setting.

Cardiology Specialties

Finerenone Efficacy and Safety Across Frailty Levels in Heart Failure: Insights from the FINEARTS-HF Trial

By MedXY 09/13/2025

This analysis of the FINEARTS-HF trial reveals that finerenone reduces cardiovascular death and heart failure worsening regardless of frailty status, without increasing adverse events, supporting its use in frail patients with HFmrEF or HFpEF.

Cardiology Clinical Updates Family Medicine & Nutrition Radiology Specialties

CT Angiography Enhances Lifestyle and Prevention Uptake in Cardiovascular Risk Management: Insights from SCOT-HEART 2 Substudy

By MedXY 09/13/2025

A nested substudy from SCOT-HEART 2 reveals coronary CT angiography modestly improves healthy lifestyle adherence, preventive therapy acceptance, and risk factor modification compared to traditional cardiovascular risk scoring in asymptomatic individuals at risk.

Cardiology Specialties

Baxdrostat: A Promising New Agent for Managing Uncontrolled and Resistant Hypertension

By MedXY 09/11/2025

Baxdrostat, a novel aldosterone synthase inhibitor, significantly reduces systolic blood pressure in patients with uncontrolled or resistant hypertension, offering a new therapeutic option with a favorable safety profile.

Cardiology Specialties

Catheter Ablation vs Drug Therapy for Atrial Fibrillation: Insights from the CABANA Trial by Nonmodifiable Risk Profiles

By MedXY 09/11/2025

This secondary analysis of the CABANA trial reveals catheter ablation significantly benefits AF patients with fewer than three nonmodifiable recurrence risk factors, underscoring the potential for personalized treatment strategies.

Cardiology news Specialties

Evaluating β-Blocker Use and Health Status in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the TOPCAT Trial

By MedXY 09/11/2025

This analysis of the TOPCAT trial cohort evaluates the association between β-blocker use and health status in HFpEF patients, revealing no significant impact on baseline quality of life or modification of spironolactone benefits.

Cardiology Clinical Updates General Surgery Specialties

Preoperative Cardiovascular Risk Does Not Alter Outcomes of Renin-Angiotensin System Inhibitor Use Before Major Noncardiac Surgery: Insights from a Secondary Analysis of the STOP-or-NOT Trial

By MedXY 09/11/2025

A secondary analysis of the STOP-or-NOT trial shows that preoperative cardiovascular risk stratification does not impact postoperative outcomes related to continuing or discontinuing renin-angiotensin system inhibitors before major noncardiac surgery.

Cardiology Clinical Updates Specialties

Medication Adherence in Hypertension: Insights from the TEAMLET Cluster Randomized Clinical Trial and Related Advances

By MedXY 09/11/2025

TEAMLET trial reveals limited impact of EHR-pharmacy linked interventions on medication adherence in hypertension, highlighting complexity of adherence barriers and the need for multifaceted, patient-centered strategies.

Cardiology Diabetes & Endocrinology news Specialties

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

By MedXY 09/10/2025

A secondary analysis of the EAST-AFNET 4 trial shows early rhythm control therapy effectively reduces cardiovascular events in atrial fibrillation patients regardless of diabetes status or obesity, supporting its broad clinical use.

Cardiology Clinical Updates Diabetes & Endocrinology Specialties

Mobile Text Messaging Enhances Glycemic and Blood Pressure Control in Adults with Uncontrolled Type 2 Diabetes

By MedXY 09/10/2025

A randomized trial in China shows that a 12-month mobile message-based intervention modestly improves HbA1c and systolic blood pressure in patients with uncontrolled type 2 diabetes, supporting mHealth strategies to manage cardiovascular risks.

Cardiology Clinical Updates news Nursing & care Specialties

Multidomain Rehabilitation Reduces Cardiovascular Events in Older Adults Post-Myocardial Infarction: Insights from the PIpELINe Trial

By MedXY 09/10/2025

A multidomain rehabilitation program combining cardiovascular risk control, dietary counseling, and exercise significantly lowers the risk of cardiovascular death or unplanned hospitalization within one year in older myocardial infarction survivors with impaired physical performance.

Cardiology Specialties

Aficamten Versus Metoprolol: A New Era in Treating Obstructive Hypertrophic Cardiomyopathy

By MedXY 09/10/2025

A multicenter trial demonstrates that aficamten monotherapy outperforms metoprolol in improving exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM).

Cardiology news Specialties

Evaluating Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Insights from the ODYSSEY-HCM Trial

By MedXY 09/10/2025

A phase 3 trial found mavacamten did not significantly improve exercise capacity or symptoms in adults with symptomatic nonobstructive hypertrophic cardiomyopathy compared to placebo, despite its efficacy in obstructive HCM.